Methyltransferases in Development and Disease
Loss-of-function (LOF) genetic screens, using pooled shRNA libraries (Bric et al., 2009; Gargiulo et al., 2013; Kaelin, 2009; Lin et al., 2012; Mills et al., 2013; Prahallad et al., 2012), CRISPR/Cas9 libraries (Cong et al., 2013), or arrayed RNAi libraries (Chia et al., 2010) can be successfully exploited to identify genes that drive or inhibit development, cell differentiation or tumorigenesis. We believe that phenotype-driven forward genetic screens are the ideal approach to identify novel biomarkers for therapeutic decisions as well as direct targets for intervention (druggable members of the methyltransferase family of enzymes) (Richon et al., 2011) for the cure of a variety of human cancers or to instruct cell type specification.
a fundamental part of the work done in the lab deals with large datasets deriving from Chip-Sequencing profiles (of Transcription Factors/co-factors or Histone Post Translational Modifications), DNA methylation landscapes or RNA-Sequencing profiles of wild-type or PRMT/PRDM depleted cells or tissues. We also actively collaborate with other groups both internationally and within IMCB, providing our expertise in computational biology (Beillard et al., 2012; Filipponi et al., 2013; Jachowicz et al., 2013; Tsai et al., 2013; Wang et al., 2014).
I am currently an Associate Professor in the department of Oncological Sciences at Icahn School of Medicine at Mount Sinai and a Snr.PI and Coordinator of the Program in Epigenetics and Diseases at IMCB in Singapore.